CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...